MAP1LC3A and ovarian carcinoma: LC3 has been reported in several tumors (including ovarian cancer (Shen et al. 2008), brain cancer (Ghavami et al. 2014), colorectal cancer (Wu et al. 2015), prostate cancer (Zhang et al. 2017), breast cancer (Jiang et al. 2017), melanoma (Segala et al. 2017).